Investigational ADC Improves PFS in Metastatic Breast Cancer

Datopotamab deruxtecan led to better progression-free survival and safety compared with standard chemotherapy in patients with metastatic HER-2 negative breast cancer.

Related Keywords

Boston ,Massachusetts ,United States ,New York ,Memorial Sloan Kettering Cancer Center ,Sarat Chandarlapaty ,Aditya Bardia ,Cancer Center ,European Society For Medical Oncology Congress ,Mass General Cancer Center ,Medical Oncology ,Metastatic Breast Carcinoma ,Breast Cancer ,Alignant Breast Neoplasm ,Chemotherapy ,Her2 Negative Breast Cancer ,Her2 Breast Cancer ,Biologic Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Breast ,Toxicology ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Antibody Drug Conjugates Adcs ,Endocrine Therapy ,Hodgkins Lympho ,